[Federal Register: February 27, 2003 (Volume 68, Number 39)]
[Notices]
[Page 9088-9089]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr27fe03-92]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Cooperative Research and Development Agreement
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC) National
Immunization Program (NIP) is seeking a Cooperative Research and
Development Agreement (CRADA) partner for collaboration in the
development of a Vaccine Management Software (VACMAN) dynamic link
library (DLL) component to interface with immunization information
systems. The current DLL is compatible to VACMAN version 2.6x and will
not be compatible when VACMAN is upgraded to version 3.
Because CRADAs are designed to facilitate the development of
scientific and technological knowledge into useful, marketable
products, a great deal of freedom is given to Federal agencies in
implementing collaborative research. The CDC may accept staff,
facilities, equipment, supplies, and money from the other participants
in a CRADA; CDC may provide staff, facilities, equipment, and supplies
to the project. CDC may not provide funds to the other participants in
a CRADA. This opportunity is available until 30 days after publication
of this notice in the Federal Register. Respondents may be provided a
longer period of time to furnish additional information if CDC finds
this necessary.
FOR FURTHER INFORMATION CONTACT:
Technical: Terry Boyd, Data Management Division, National
Immunization Program, Centers for Disease Control and Prevention (CDC),
1600 Clifton Rd., NE., Mailstop E-62, Atlanta, GA 30333, telephone
(404) 639-8584.
Business: Janet Kelly, Data Management Division, National
Immunization Program, Centers for Disease Control and Prevention (CDC),
1600 Clifton Rd., NE., Mailstop E-62, Atlanta, GA 30333, telephone
(404) 639-8735.
SUPPLEMENTARY INFORMATION: The VACMAN application was developed by the
CDC NIP and is used by CDC Immunization Grant programs to purchase
vaccines through a Vaccine
[[Page 9089]]
Ordering and Distribution System. The VACMAN DLL interface component
allows immunization information systems to interface with VACMAN.
The CDC/NIP Development Team will work with respondent to develop
and promote a product that will support VACMAN connectivity with
immunization information systems and other applications that might
exist on different operating systems. Respondent will be given access
to VACMAN 3 database specifications and business rules. Respondent will
maintain the code such that it is constantly kept updated accordingly
as changes in the VACMAN product occurs. CDC/NIP requires the use of
the source code and free distribution rights for the object code, which
may include vendors, to ensure all available products can interact with
VACMAN consistently and that all Grant programs have the opportunity to
integrate VACMAN with their other processes for properly managing their
vaccines.
Applicant submissions will be judged according to the following
criteria:
1. Evidence of expertise in software development and supporting
data (e.g., resumes) of qualifications for the principle investigator
who would be involved in the CRADA.
2. Specific operating systems and development languages proposed
for development of the DLL.
3. Evidence of commitment for development to release to Grant
programs, including vendors, the compiled components along with all
appropriate documentation such as Application Program Interface
documentation.
With respect to Government Intellectual Property (IP) rights to any
invention not made solely by a CRADA partner's employees for which a
patent or other IP application is filed, CDC has the authority to grant
to the CRADA partner an exclusive option to elect an exclusive or
nonexclusive commercialization license. This option does not apply to
inventions conceived prior to the effective date of a CRADA that are
reduced to practice under the CRADA, if prior to that reduction to
practice, CDC has filed a patent application on the invention and has
licensed it or offered to license it to a third party. The terms of the
license will fairly reflect the nature of the invention, the relative
contributions of the Parties to the invention and the CRADA, the risks
incurred by the CRADA partner and the costs of subsequent research and
development needed to bring the invention to the marketplace. The field
of use of the license will be commensurate with the scope of the
Research Plan.
This CRADA is proposed and implemented under the 1986 Federal
Technology Transfer Act: Public Law 99-502, as amended.
The responses must be made to: Lisa Blake-DiSpigna, Technology
Development Coordinator, National Center for Infectious Diseases,
Centers for Disease Control and Prevention (CDC), 1600 Clifton Rd. NE.,
Mailstop C-19, Atlanta, GA 30333.
Dated: February 21, 2003.
Joseph R. Carter,
Associate Director for Management and Operations, Centers for Disease
Control and Prevention (CDC).
[FR Doc. 03-4599 Filed 2-26-03; 8:45 am]
BILLING CODE 4163-18-P